EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 3.0

HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives

Abdallah E Abdallah iD

RSC Advances · 2026 · 16 (4) · 3430-3442

DOI: 10.1039/d5ra09034b ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift RSC Advances, 2026. Verfasst von Abdallah E Abdallah. Beteiligte Einrichtung: Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University Cairo 11884 Egypt abdulla_emara@azhar.ed…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In an attempt to collect clinical data about HDAC inhibitors as very significant anticancer drugs, we aimed to compare data and reveal the impact of the structural features to help – develop better cancer therapy.

Autor:innen und Institutionen

  • Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University Cairo 11884 Egypt abdulla_emara@azhar.edu.eg.

ORCID-Profile: Abdallah E Abdallah

Zitieren

APA

Abdallah, A. E. (2026). HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives. RSC Advances, 16(4), 3430-3442. https://doi.org/10.1039/d5ra09034b

Vancouver

Abdallah AE. HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives. RSC Advances. 2026;16(4):3430-3442. doi:10.1039/d5ra09034b

BibTeX
@article{Abdallah2026,
  author = {Abdallah, Abdallah E},
  title = {HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives},
  journal = {RSC Advances},
  year = {2026},
  volume = {16},
  number = {4},
  pages = {3430--3442},
  doi = {10.1039/d5ra09034b}
}
Kostenlos starten →